enzastaurin + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a **combination regimen** consisting of **enzastaurin** (a small-molecule inhibitor of protein kinase C beta and related pathways), combined with **rituximab** (a monoclonal antibody targeting CD20), **cyclophosphamide** (an alkylating chemotherapy agent), **doxorubicin** (an anthracycline chemotherapy), **vincristine** (a plant alkaloid chemotherapy), and **prednisone** (a corticosteroid). This regimen is an experimental extension of the standard R-CHOP therapy, being investigated for use in **diffuse large B-cell lymphoma (DLBCL)**, particularly in patients at high risk or with DGM1 positivity[1][5][7][9]. The addition of enzastaurin targets PKC beta signaling, potentially improving outcomes over R-CHOP alone.

Other names

R-CHOP + enzastaurin